Triple therapy effective after just one treatment cycle in AMD

Article

For most patients with choroidal neovascularization (CNV) resulting from age-related macular degeneration (AMD), triple therapy offers significant and sustained visual improvement after just one cycle of treatment.

For most patients with choroidal neovascularization (CNV) resulting from age-related macular degeneration (AMD), triple therapy offers significant and sustained visual improvement after just one cycle of treatment, according to a paper published in the February issue of Retina.

Albert Augustin, MD and colleagues from the Klinikum Karlsruhe, Karlsruhe, Germany, conducted a prospective, non-comparative, interventional case series including 104 subjects with CNV. Veterporfin photodynamic therapy (PDT) was administered first with a reduced light dose (42 J/cm). Approximately 16 hours later, dexamethasone (800 µg) and bevacizumab (1.5 mg) were injected intravitreally. Patients were followed up very six weeks, undergoing visual acuity (VA) and intraocular pressure (IOP) measurements, slit-lamp and ophthalmoscopic examinations and optical coherence tomography (OCT). Fluorescein angiography was performed at three-month intervals.

Each subject received one cycle of triple therapy and five received a second cycle because of remaining CNV activity. Eighteen patients received an additional intravitreal injection of bevacizumab. The mean follow-up period was 40 weeks.

Follow-up examinations revealed a mean increase in VA of 1.8 lines (p<0.01) and a mean decrease in retinal thickness of 182 µm (p<0.01). No serious adverse events were observed.

The authors concluded that triple therapy for CNV resulting from AMD, can result in significant and sustained improvement in VA. In addition, the therapy is well tolerated and offers greater convenience for patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
Related Content
© 2025 MJH Life Sciences

All rights reserved.